WSTAM
GNMK

Wilbanks Smith & Thomas Asset Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-672
Closed -$5K – 1465
2018
Q3 		$5K Buy
+672
New +$4.93K ﹤0.01% 1247

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's GNMK Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2018, closing a stake of 672 shares — an estimated $5K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in GNMK in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 103 funds tracked by Wall St. Rank hold GNMK as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining GenMark Diagnostics, Inc position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 672 GenMark Diagnostics, Inc shares in Q4 2018, an estimated $5K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in GenMark Diagnostics, Inc in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's GenMark Diagnostics, Inc position peaked at $5K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.